Baicalein disrupts the hypoxia-glycolysis-fibrosis axis in idiopathic pulmonary fibrosis via HIF-1α/FHL2 suppression
Baicalein ameliorates idiopathic pulmonary fibrosis by disrupting the HIF-1α/FHL2 phase-separated transcriptional hub, thereby suppressing the hypoxia-driven glycolytic shift and subsequent lactate-mediated histone lactylation that fuel fibrotic progression.